Alpha galactosylceramide liposomal - REGiMMUNE

Drug Profile

Alpha galactosylceramide liposomal - REGiMMUNE

Alternative Names: KRN-7000 liposomal; liposomal KRN-7000; liposomal RGI-7000; RGI 3100; RGI-2001; RGI-7000 liposomal; ToleroVax

Latest Information Update: 14 Mar 2017

Price : $50

At a glance

  • Originator REGiMMUNE
  • Developer JDRF; Pfizer; REGiMMUNE
  • Class Adjuvants; Antineoplastics; Galactosylceramides; Small molecules
  • Mechanism of Action Blood coagulation factor replacements; Enzyme replacements; Galactosylceramidase replacements; Immunosuppressants; Natural killer cell stimulants; Regulatory T-lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Graft-versus-host disease
  • Preclinical Haemophilia; Lysosomal storage diseases; Type 1 diabetes mellitus

Most Recent Events

  • 09 Mar 2017 Immunogenicity data from a phase I/IIa trial in Graft-versus-Host Disease released by REGiMMUNE
  • 21 Oct 2016 RGI 3100 is still in preclinical development for Type-1 diabetes in Japan (REGiMMUNE pipeline, October 2016)
  • 19 Oct 2016 Preclinical trials in Haemophilia in Japan before October 2016 (REGiMMUNE pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top